

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 - Pipeline Review, H1 2020

https://marketpublishers.com/r/GF672CB8CAFBEN.html

Date: March 2020

Pages: 32

Price: US\$ 3,500.00 (Single User License)

ID: GF672CB8CAFBEN

Abstracts

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 - Pipeline Review, H1 2020

SUMMARY

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) pipeline Target constitutes close to 5 molecules. The latest report Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Gamma-aminobutyric acid receptor subunit alpha-2 is a protein that in humans is encoded by the GABRA2 gene. It plays an important role in the formation of functional inhibitory GABAergic synapses in addition to mediating synaptic inhibition as a GABA-gated ion channel. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System and Dermatology which include indications Anxiety Disorders, Epilepsy, Neuropathic Pain (Neuralgia), Depression, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Fibromyalgia (Fibromyalgia Syndrome) and Pruritus.

Furthermore, this report also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics development with respective active and dormant or discontinued projects.



Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2)

The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics



REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Overview

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Companies Involved in Therapeutics Development

Baergic Bio Inc

Cerevel Therapeutics LLC

NeuroCycle Therapeutics Inc

Saniona AB

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Drug Profiles

BAER-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVL-865 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-711 - Drug Profile

Product Description



Mechanism Of Action

R&D Progress

Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Dormant Products

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Discontinued Products

Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit

Alpha 2 or GABRA2) - Product Development Milestones

Featured News & Press Releases

Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel

a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy

Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and

pharmacokinetics results from phase 1 trial of CVL-865

Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in

Neurology on its most advanced investigational Epilepsy treatment

Feb 18, 2019: Sanionas SAN711 selected for clinical studies in itching and pain

Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet

Syndrome drug candidate NCT10004

Dec 04, 2017: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for

Neuropathic Pain and Chronic Itching

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Baergic Bio Inc, H1 2020

Pipeline by Cerevel Therapeutics LLC, H1 2020

Pipeline by NeuroCycle Therapeutics Inc, H1 2020

Pipeline by Saniona AB, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Baergic Bio Inc Cerevel Therapeutics LLC NeuroCycle Therapeutics Inc Saniona AB



I would like to order

Product name: Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/GF672CB8CAFBEN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GF672CB8CAFBEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970